Abstract: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effector. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
April 28, 2011
Publication date:
August 15, 2013
Applicants:
PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
Abstract: Nutritional compositions that mimic whole foods and methods of using the nutritional compositions are provided. The nutritional compositions may include an increased number and variety of fruits and vegetables, an increased variety of macronutrient sources and an increased amount of other components that are found in whole foods. The nutritional compositions may also include ethnicity-specific meals and organic ingredients and provide emotional appeal to the patient and/or the patient's caregiver.
Type:
Application
Filed:
June 28, 2011
Publication date:
August 15, 2013
Applicant:
NESTEC S.A.
Inventors:
Jennifer Mager, Zamzam Fariba Roughead, Heidi Storm, James Scott Teresi
Abstract: A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype.
Type:
Grant
Filed:
February 16, 2007
Date of Patent:
August 13, 2013
Assignee:
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Inventors:
J. Andrea McCart, David L. Bartlett, Bernard Moss
Abstract: Disclosed are methods of administering at least two Bacillus strains to a pig, such as female breeding stock, nursery pigs, or other pigs. The Bacillus strains inhibit Clostridium in litters borne to the pig. The Bacillus strains also are useful when administered to herds lacking symptoms of Clostridium infection. Administration of the Bacillus strains improves performance of female breeding stock and in piglets borne by the female breeding stock.
Type:
Grant
Filed:
August 18, 2011
Date of Patent:
August 13, 2013
Assignee:
DuPont Nutrition Biosciences ApS
Inventors:
Thomas G. Rehberger, Mari Ellen Davis, Ashley Baker
Abstract: Probiotic composition(s) and/or process(es) thereof. Processes may include applying Janthinobacterium, for example Janthinobacterium lividum, over a host and/or host area(s) to minimize microbe(s) and/or maximize therapeutic effects. A process to minimize a microbe may include applying to skin a composition including isolated Janthinobacterium lividum and a pharmaceutically acceptable carrier. Probiotic composition(s) and/or process(es) thereof may include relatively heat tolerant Janthinobacterium lividum which may produce metabolites, for example violacein up to approximately 29° C. Probiotic composition(s) and/or process(es) thereof may include Janthinobacterium lividum between approximately 25×106 and 6.4×107 cells. Probiotic composition(s) and/or process(es) thereof may include Janthinobacterium lividum which has and/or produces between approximately 18 ?M and 129 ?M of violacein. Probiotic composition(s) and/or process(es) thereof may include a stimulant to maximize metabolites.
Abstract: The present invention relates to a fiber-assembled tissue construct comprising at least one sinusoid unit, the unit comprising at least two polymeric fibers arranged in a sinusoid structure and fused together, each of said fibers comprising a porous matrix supporting biological components encapsulated in the fiber, wherein the biological components are patterned in three-dimensions within the construct.
Type:
Application
Filed:
February 19, 2010
Publication date:
August 8, 2013
Inventors:
Andrew Chwee Aun Wan, Meng Fatt Leong, Jackie Y. Ying, Jerry Kah Chin Toh
Abstract: The present invention relates to platelet fractions which can be obtained from placental blood, with high concentrations of platelet factors as well as gels and lysates deriving therefrom. The invention further relates to methods for preparing said platelet fractions from placental blood, and to the uses thereof as such or as platelet gels or as lysates.
Type:
Grant
Filed:
July 14, 2009
Date of Patent:
August 6, 2013
Assignee:
Fondazione IRCCS “CA' Granda—Ospedale Maggiore Policlinico”
Inventors:
Paolo Rebulla, Lorenza Lazzari, Valentina Parazzi, Noemi Greppi
Abstract: There is provided a vaccine for controlling Clostridium perfringens in animals, and particularly necrotic enteritis in poultry. The vaccine may comprise a C. perfringens antigenic polypeptide or variant thereof, a nucleic acid encoding the C. perfringens antigenic polypeptide or variant thereof, or a recombinant cell producing the C. perfringens antigenic polypeptide or variant thereof.
Type:
Grant
Filed:
May 30, 2008
Date of Patent:
August 6, 2013
Assignee:
The University of Guelph
Inventors:
John Prescott, Raveendra Kulkarni, Valeria Parreira, Shayan Sharif
Abstract: Methods and apparatuses for delivery of biologically active material and/or sensors to a target organ or system. The apparatuses allow for specific, controlled delivery of the biologically active material and targeted placement of sensors. The apparatuses may be fabricated from cellular and/or acellular biological active components to promote integration of sensors into tissue and achieve appropriate release of biologically active molecules. The apparatuses may be fabricated from plasma-containing materials or other biopolymers such that the apparatus will resorbed into the tissue following insertion. The biologically active cellular or acellular component may be incorporated into that material may then serve as the source of the therapeutic biologically active component. The apparatus may take the form of a screw, though numerous shapes arc contemplated.
Type:
Application
Filed:
January 28, 2013
Publication date:
August 1, 2013
Applicants:
CARNEGIE MELLON UNIVERSITY, University of Pittsburgh-of the Commonwealth System of Higher Education
Inventors:
David SCHWARTZMAN, Lee E. Weiss, Phil Gordon Campbell, Gary K. Fedder
Abstract: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effector. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.
Abstract: A microorganism having an ability to oxidize sulfur even at high chloride ion concentration is provided. Specifically, a microorganism belonging to the genus Acidithiobacillus having the ability to oxidize sulfur even at high chloride ion concentration is provided. A method for bacterial leaching of copper sulfide ores and a method for improving alkaline soil using the microorganism are also provided.
Abstract: An exemplary embodiment providing one or more improvements includes feeding animals with probiotic microbes encapsulated in a mixture of xanthan gum and chitosan, or in gelatin, specifically Pediococcus acidilactici and Saccharomyces boulardii. Such encapsulation protects the viability of the probiotic microbes against unfavorable temperatures. An exemplary embodiment providing one or more improvements includes methods of using viable probiotics in therapy of birds and mammals infected with infectious diseases. Probiotics acted as adjuvants in stimulating antibody reaction and stimulated a cellular immunity response. In particular, probiotics were shown to reduce the number of viable oocytes from fecal samples, stimulate antibody production, and stimulate of proliferation of splenocytes in chickens infected with Eimeria. In addition, probiotics were shown to relieve symptoms of parvovirus infection in dogs.
Abstract: A cosmetic composition with superior moisturizing benefits comprising from approximately 0.3% to approximately 0.9% by weight of bio-chelated mineral blend comprising silicon, magnesium, copper, iron, zinc, and calcium, and at least approximately 85.0% by weight of a humectant blend. Preferably, the bio-chelated mineral blend comprise Saccharomyces zinc ferment, Saccharomyces copper ferment, Saccharomyces magnesium ferment, Saccharomyces iron ferment, Saccharomyces silicon ferment, and Saccharomyces calcium ferment in equal amounts, more preferably from approximately 0.05% to approximately 0.15% by weight of each component. The humectant blend preferably comprises glycerin, beet root extract, and Aloe barbadensis leaf polysaccharides.
Type:
Grant
Filed:
December 2, 2009
Date of Patent:
July 30, 2013
Assignee:
Bath and Body Works Brand Management, Inc.
Abstract: An industrial strain of a unicellular green algae Parachlorella nurekis 1904 KIEG deposited in the Culture Collection of Algae and Protozoa (CCAP), Scottish Marine Institute, Dunbeg, OBAN, Argyll, PA37 1QA, Scotland, UK, CCAP No. 259/1. A method for eradication of at least one of cyanobacteria, bacteria and fungi comprises treating the at least one of cyanobacteria, bacteria and fungi with an industrial strain of the unicellular green algae Parachlorella nurekis 1904 KIEG deposited in the Culture Collection of Algae and Protozoa (CCAP), Scottish Marine Institute, Dunbeg, OBAN, Argyll, PA37 1QA, Scotland, UK, CCAP No. 259/1.
Abstract: Compositions and methods useful for reducing or eliminating the presence of pathogens in meat or meat products are disclosed. Administration of one or more lactic acid producing microorganisms to a live animal, to a carcass, to meat, to meat products, or in animal feed results in significant reductions in the amount of pathogens potentially harmful to humans when ingested. Synergistic effects can be achieved with the administration of multiple strains of microorganisms.
Abstract: Disclosed herein are systems for delivery of one or more molecules (such as a drug, for example, a small molecule, polypeptide, and/or nucleic acid) to a subject, for example to a targeted location in the subject. In some embodiments, the delivery system includes an encapsulated inducing agent or repressing agent and a plurality of cells. In some examples, the inducing agent or repressing agent and the cells are each separately encapsulated. In other examples, the encapsulated inducing agent or repressing agent and the cells are co-encapsulated. The cells include one or more genes which are operably linked to an inducible promoter or a repressible promoter which is inducible or repressible by the encapsulated inducing agent or repressing agent, respectively. Methods of use of the delivery systems, for example to treat or inhibit a disease or disorder in a subject, are also disclosed.
Type:
Application
Filed:
January 24, 2013
Publication date:
July 25, 2013
Applicants:
Brown University, The United States Government as Represented by the Department of Veterans Affairs
Inventors:
The United States Government as Represented by the Department of Veterans Affairs, Brown University
Abstract: Described are composite materials and methods of making and using them for the storage and delivery of unstable drugs or biologics. In certain embodiments, the composite material comprises a support member, comprising a plurality of pores extending through the support member; a macroporous cross-linked gel, comprising a plurality of macropores; a therapeutic agent; and a stabilizing agent.
Abstract: This invention relates to methods of treating amyotrophic lateral sclerosis. In particular, the invention provides for methods of treating amyotrophic lateral sclerosis by administering umbilical cord tissue-derived cells, an effective amount of a substantially homogenous population of umbilical cord tissue-derived cells or a pharmaceutical composition comprising umbilical cord tissue-derived cells to a patient.
Type:
Grant
Filed:
February 14, 2011
Date of Patent:
July 23, 2013
Assignee:
Advanced Technologies and Regenerative Medicine, LLC
Inventors:
Anna Gosiewska, Alexander M. Harmon, Anthony J. Kihm, Carri H. Fang, Sridevi Dhanaraj
Abstract: The present invention provides a method of producing a protein-based encapsulate, said method comprising: providing an aqueous solution of a protein that is capable of forming disulfide cross-links; submitting said aqueous solution to a protein activation treatment to produce an aqueous suspension of activated protein aggregates, said suspension having a reactivity of at least 5.0 ?mol thiol groups per gram of activated protein aggregates as determined in the Ellman's assay; dispensing said aqueous suspension in a gas or a water-immiscible liquid to produce suspension droplets having a diameter of 0.1-500 ?m; and forming disulfide cross-links between the activated protein aggregates by contacting the activated protein aggregates with an oxidizing agent, optionally after said activated protein aggregates have been partially cross-linked by forming disulfide cross-links by means of heat treatment or by pressurization to a pressure in excess of 50 MPa.
Type:
Application
Filed:
May 21, 2008
Publication date:
July 18, 2013
Inventors:
Aart Cornelis Alting, Theodorus Arnoldus Gerardus Floris, Fanny Chantal Jacqueline Weinbreck, Jeroen Grandia, Freddie Van De Velde, Igor Bodnár
Abstract: Modified antigen presenting cells provided herein have improved lifespan and immunogenicity compared to unmodified antigen presenting cells, and are useful for immunotherapy. The modified antigen presenting cells express an altered protein kinase, referred to herein as “Akt.” The altered Akt associates with the cell membrane with greater frequency than unaltered Akt, and is referred to herein as “membrane-targeted Akt.
Type:
Grant
Filed:
September 19, 2012
Date of Patent:
July 16, 2013
Assignee:
Bellicum Pharmaceuticals, Inc.
Inventors:
Dongsu Park, David Spencer, Natalia Lapteva
Abstract: Bacteria with improved survival under toxic and oxidative stress and methods of using the same for bioremediation are described. Many bacteria such as Escherichia coli have been found to naturally reduce toxic pollutants into a less toxic form, such as by reducing Chromium (VI) to Chromium (III). Reducing such toxins generates damaging reactive oxygen species, so it is important to find a defense for these bacteria against the associated oxidative stress. Trehalose is a small biomolecule that has been shown to protect bacteria from various types of stress by accumulating within the cells. The present invention is directed to bacteria genetically modified to overexpress trehalose biosynthesis genes. The bacteria demonstrate improved viability when challenged with toxins and oxidative stress. The present invention provides inexpensive and beneficial bacteria and methods for environmental remediation.
Abstract: Whole-cell vaccines and methods for their use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria. The present invention involves a method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme is reduced, thereby modifying the microbe so that it increases immunogenicity. Also, the present invention provides a method of incrementally modifying enzyme activity to produce incrementally attenuated mutants of the microbe from which an effective vaccine candidate can be selected.
Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.
Type:
Grant
Filed:
June 11, 2009
Date of Patent:
July 9, 2013
Assignee:
Tissue Regeneration Therapeutics Inc.
Inventors:
John E. Davies, Dolores Baksh, Rahul Sarugaser, Morris Hosseini, Antony D. S. Lickorish
Abstract: Methods and compositions for treating an autoimmune disease, such as new onset type 1 diabetes (T1D) in a subject using autologous or allogeneic mesenchymal stem cells administered to the subject prior to autoimmune-induced complete depletion of insulin-producing pancreatic beta cells, e.g., within six months of new onset type 1 diabetes (T1D) diagnosis or prior to the onset of disease in a subject determined to be at high risk for T1D.
Type:
Grant
Filed:
July 28, 2011
Date of Patent:
July 9, 2013
Assignee:
Genzyme Corporation
Inventors:
Tracey Lodie, Michele Youd, Ross Tubo, Scott Eisenbeis
Abstract: The invention relates to compositions for preparing a beverage, the compositions comprise a microorganism and/or an enzyme capable of hydrolysing chlorogenic acids of a coffee extract to phenolic acids. When a beverage prepared with the compositions of the invention is consumed chlorogenic acids present in coffee extract is hydrolysed to improve antioxidant and/or anti-inflammatory properties compared to a similar conventional beverage.
Type:
Grant
Filed:
March 12, 2009
Date of Patent:
July 9, 2013
Assignee:
Nestec S.A.
Inventors:
Rachid Bel-Rhlid, Karin Kraehenbuehl, Christophe Cavin, Thomas Wolfgang Raab, Nicolas Page
Abstract: A method of treating cancer by introducing heat into cancerous tissue and delivering a liposome containing an active agent or a thermo-activated drug, gene or virus to said tissue. The heat delivered is sufficient to release the active agent or activate the thermo-activated drug, gene or virus. The cancer can be esophageal cancer. The liposome containing an active agent or a thermo-activated drug, gene or virus can be a thermosensitive liposome. The active agent can be an anti-neoplastic agent, for example doxorubicin.
Abstract: A sterile pharmaceutically acceptable aqueous solution, which solution is provided in a sealed container and comprises: a pharmaceutically acceptable aqueous solvent; viral particles or a physiologically active polypeptide; an excipient selected from a polyethyleneimine; a compound of formula (I) or a physiologically acceptable salt or ester thereof; or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and optionally, one or more sugars.
Type:
Application
Filed:
March 31, 2011
Publication date:
June 27, 2013
Inventors:
Jeffrey Drew, David Woodward, John Bainbridge, Amanda Corteyn
Abstract: A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Tooth stem cells may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem cells are removed and isolated from the other teeth tissue, the hard tooth may be ground into a base material for the manufacture of a porous matrix into which the tooth stem cells can be added. Additionally, soft tissue from the harvested tooth may be used as a carrier scaffold for soft tissue applications such as meniscal or cartilage repair.
Abstract: A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Tooth stem cells may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem cells are removed and isolated from the other teeth tissue, the hard tooth may be ground into a base material for the manufacture of a porous matrix into which the tooth stem cells can be added. Additionally, soft tissue from the harvested tooth may be used as a carrier scaffold for soft tissue applications such as meniscal or cartilage repair.
Abstract: The invention relates to the isolation and use of hematopoietic and embryonic stem cells. Additionally, the inventors identified the peritoneal cavity as a new source of hematopoietic stem cells. In one embodiment, the invention provides methods of isolating progenitor and/or stem cells from the peritoneal cavity. In another embodiment, the invention provides methods of transporting progenitor and/or stem cells from the peritoneal cavity to another organ. In another embodiment, the present invention provides methods of regenerating bioengineered tissues and/or reconstituting an hematopoietic system.
Type:
Grant
Filed:
February 12, 2008
Date of Patent:
June 18, 2013
Assignee:
Cedars-Sinai Medical Center
Inventors:
Behrooz Sharifi, Lai Wang, Prediman K. Shah
Abstract: The invention relates to methods of improving the osteoinductivity of calcium phosphate materials, to calcium phosphate materials having improved osteoinductivity as well as bone (re)generation scaffolds produced therefrom and to the use of such materials and scaffolds in methods of treatment.
Type:
Grant
Filed:
April 21, 2006
Date of Patent:
June 11, 2013
Assignee:
Progentix Orthobiology B.V.
Inventors:
Huipin Yuan, Joost Dick De Bruijn, Klaas De Groot
Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.
Type:
Grant
Filed:
August 21, 2009
Date of Patent:
June 11, 2013
Assignees:
Tokyo Metropolitan Institute of Medical Science, Toray Industries, Inc.
Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
Type:
Grant
Filed:
February 12, 2008
Date of Patent:
June 11, 2013
Assignee:
Anthrogenesis Corporation
Inventors:
James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
Abstract: The invention is directed to methods for treating coagulation disorders, in particular, hemophilia. Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents and/or treatment modalities.
Abstract: The use of docosahexaenoic acid in the manufacture of a composition for administration to a pregnant woman for reducing the risk of development of overweight or obesity of the baby in infancy and/or early childhood.
Abstract: Methods and compositions for the site-selective delivery of a gene to a site within the body of an animal where virus not encapsulated within the microbubbles is inactivated, for example by treatment with a virus-inactivating agent.
Type:
Grant
Filed:
August 22, 2007
Date of Patent:
June 4, 2013
Assignee:
Temple University—Of The Commonwealth System of High Education
Abstract: A method for manufacturing a drug-delivery composition includes providing at least one pharmaceutically active compound, a dry powder comprising at least a polymer, and an aqueous solution. The dry powder, the pharmaceutically active compound and the aqueous solution are mixed to form a paste-like or semi-solid drug-delivery composition, wherein the aqueous solution is added in an amount of less than or equal to twice the total dry mass of the dry powder.
Type:
Application
Filed:
November 30, 2011
Publication date:
May 30, 2013
Inventors:
Andreas Voigt, Jörg Kriwanek, Scott Hampton, Andreas Reiff, Sonja Ludwig
Abstract: A device, and method of making the device, capable of therapeutic treatment and/or for in vitro testing of human skin. The device may be used on skin wounds for burned, injured, or diseased skin, and provides structures and functions as in normal uninjured skin, such as barrier function, which is a definitive property of normal skin. The device contains cultured dermal and epidermal cells on a biocompatible, biodegradable reticulated matrix. All or part of the cells may be autologous, from the recipient of the cultured skin device, which advantageously eliminates concerns of tissue compatibility. The cells may also be modified genetically to provide one or more factors to facilitate healing of the engrafted skin replacement, such as an angiogenic factor to stimulate growth of blood vessels.
Type:
Grant
Filed:
June 18, 2010
Date of Patent:
May 28, 2013
Assignees:
University of Cincinnati, Shriners Hospitals for Children
Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-1 mutein. More specifically, the invention provides a composition comprising a virus-like particle, and at least one IL-1 mutein linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of inflammatory diseases, and chronic autoimmune diseases, genetic diseases and cardiovascular diseases. The composition of the invention efficiently induces immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
Type:
Grant
Filed:
March 29, 2007
Date of Patent:
May 28, 2013
Assignee:
Cytos Biotechnology AG
Inventors:
Martin F. Bachmann, Gunther Spohn, Alain Tissot
Abstract: We have disclosed dicephalic amphiphiles having peptide sequences as the head groups. We have also disclosed self-assembly hydrogels prepared from the dicephalic peptide amphiphiles. These hydrogels are useful for the encapsulation and delivery of bioactives to a patient.
Type:
Application
Filed:
February 6, 2013
Publication date:
May 23, 2013
Applicant:
JOHNSON & JOHNSON CONSUMER COMPANIES, INC.
Inventor:
Johnson & Johnson Consumer Companies, Inc.
Abstract: Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen.
Abstract: A bioremediation method for accelerated biological degradation of petroleum hydrocarbons in a sea ice-covered polar region comprising contacting the petroleum hydrocarbons with an inoculum. The inoculum includes a bacterial mixture, nutrients, and an environmentally friendly carrier material. The bacterial mixture includes a plurality of cold-adapted autochthonous bacterial strains, wherein each of the bacterial strains are active at an ambient temperature of ?3° C., and wherein each of the bacterial strains has a different temperature tolerance range, a different salinity tolerance range, a different degradation spectrum, and a different potential to emulsify oil. Bacteria of the bacterial strains are immobilized on the environmentally friendly carrier material.
Abstract: A strain of Enterococcus mundtii has probiotic qualities. The strain of E. mundtii (ST4SA) produces an antimicrobial peptide which exhibits antimicrobial activity against a broad range of bacteria. An isolated nucleotide sequence codes for the antimicrobial peptide (peptide ST4SA). A process is also provided for the production of a peptide which comprises cultivating Enterococcus mundtii strain ST4SA in a nutrient medium under micro-aerophilic conditions at a temperature of between 10° C. and 45° C., until a recoverable quantity of the peptide is produced, and recovering the peptide. The isolated peptide may be used as an antimicrobial agent in a liquid formulation or a gel formulation as a topical treatment and may also be used as an antimicrobial agent following encapsulation in a polymer.
Type:
Grant
Filed:
April 26, 2011
Date of Patent:
May 21, 2013
Assignee:
CIPLA Medpro Research and Development (Pty) Ltd
Abstract: The present invention relates to the use of a particular type of adipose tissue derived mesenchymal stem cells (AD-MSCs), which exert immunosuppressive properties, in the manufacture of a pharmaceutical composition for the prevention and treatment of the graft-versus-host disease (GVHD) produced after allogeneic hematopoietic stem cell transplantation.
Type:
Grant
Filed:
December 7, 2006
Date of Patent:
May 14, 2013
Assignees:
Centro de Investigaciones Energéticas, Medioambientales y Technológicas, TiGenix, SA
Inventors:
Manuel Angel González De La Peña, Dirk Büscher, Aitor Beraza Pérez, Juan Bueren Roncero, Rosa Maria Yanez González, Maria Lamana Luzuriaga
Abstract: Disclosed are compositions and methods for classifying stem cells. The disclosure provides a way to define cells using a computational analysis.
Abstract: Novel bacteriophage strains are disclosed and their use in the production of preparations for use in the treatment of bacterial infections, particularly with drug resistant strains of bacteria of the genus Enterococcus, particularly those belonging to the species Enterococcus faecalis.
Type:
Grant
Filed:
September 27, 2009
Date of Patent:
May 14, 2013
Assignee:
Instytut Immunologii I Terapii Doswiadzalnej Pan
Inventors:
Beata Weber-Dabrowska, Andrzej Górski, Ryszard Miedzybrodzki
Abstract: The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma hyopneumoniae (M. hyo) by administering to the animal at approximately three (3) to ten (10) days of age, a single dose of an effective amount of a M. hyo vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.